scorecardresearch
Sunday, November 3, 2024
TopicSun Pharma

Topic: Sun Pharma

US drug regulator halts Sun Pharma trials on dermatological drug

Sun Pharma, India's largest drugmaker by revenue, acquired deuruxolitinib when it bought US-based Concert Pharmaceuticals for $576 million earlier this year.

US FDA asks India’s Sun Pharma to halt trials on experimental dermatological drug

Sun Pharma said FDA has also stated that patients with alopecia areata on 12 mg dose of the drug deuruxolitinib should discontinue its use, Sun Pharma said.

Sun Pharmaceutical flags revenue drop in its businesses due to ‘IT security incident’

The incident’s effect included breach of certain file systems and theft of some company and personal data, Sun Pharma said in a filing on Sunday.

Sun Pharma gets approval to test pancreatitis drug nafamostat for Covid treatment

Sun Pharma says nafamostat has shown promise in fighting against the virus in in-vitro studies conducted by 3 groups of scientists in Europe, Japan and South Korea.

China’s war on healthcare costs opens big window for India’s Sun Pharmaceuticals

China's ambitious multi-city bulk procurement program provides an opening for Indian manufacturers to compete.

Sun pharma falls after report of fresh whistle-blower complaint

Shares of India’s largest drugmaker fell as much as 13.2 percent.

On Camera

As a Hindu Canadian, I am deeply hurt by cancellation of Diwali. My community is now sidelined

Canada faces serious foreign interference issues, but these challenges must not be weaponized to unfairly target friendly and important allies like India.

Watch CutTheClutter: Flattening INR-USD rate, and debate on pros and cons of a ‘strong’ rupee

In Episode 1544 of CutTheClutter, Editor-in-Chief Shekhar Gupta looks at some top economists pointing to the pitfalls of ‘currency nationalism’ with data from 1991 to 2004.

Indian firms sanctioned by US didn’t violate laws, says MEA. Hyderabad firm that supplied to Army on list

Among 19 Indian firms sanctioned by US Treasury Dept was Lokesh Machines Ltd accused of coordinating with 'Russian defence procurement agent to import Italy-origin CNC machines'.

Xi wanted to teach India about imbalance of power. We should take a budgetary lesson from it

While we talk much about our military, we don’t put our national wallet where our mouth is. Nobody is saying we should double our defence spending, but current declining trend must be reversed.